- In July 2024, Armata Pharmaceuticals announced the successful completion of patient enrollment in its Tailwind Phase II clinical trial. The study is evaluating the efficacy of inhaled AP-PA02 in treating non-cystic fibrosis bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infections. This milestone marks a significant step forward in the development of innovative treatments for this condition
- In May 2024, Insmed Incorporated reported positive topline results from its global Phase III ASPEN study. The randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. These promising results represent a significant advancement in the development of treatments for this chronic lung condition
- In April 2024, 30 Technology announced that the European Medicines Agency (EMA) had granted approval for the Phase I/IIa NOPA trial. This study is designed to evaluate the safety, tolerability, and efficacy of nebulized Nitric Oxide Formulations in patients with non-cystic fibrosis bronchiectasis (NCFB) who have Pseudomonas aeruginosa (Pa) or other potentially pathogenic microorganisms (PPMs). The trial marks an important step in advancing treatment options for this patient population
- In November 2023, Chiesi Farmaceutici and Haisco Pharmaceutical Group entered into a Licensing Agreement to develop, manufacture, and commercialize HSK31858 for respiratory diseases outside of greater China, including Hong Kong, Macau, and Taiwan. As part of the agreement, Chiesi will provide an upfront payment, contingent milestone payments, and royalties on product sales to Haisco. This collaboration aims to expand the reach of HSK31858 in treating respiratory conditions globally
